Krystal Biotech, Inc. $KRYS Shares Sold by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC reduced its holdings in Krystal Biotech by 13.5%, selling 10,100 shares and owning 64,601 shares post-sale, which are valued at approximately $11.65 million.
• Institutional investors collectively own 86.29% of Krystal Biotech, with notable increases in stakes from firms like Brooklyn Investment Group and Fifth Third Bancorp during the first quarter.
• Krystal Biotech reported earnings of $1.29 per share, exceeding analysts' expectations, alongside a revenue of $96.04 million for the quarter, which is also above estimates.

Voya Investment Management LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 13.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,601 shares of the company's stock after selling 10,100 shares during the quarter. Voya Investment Management LLC owned about 0.22% of Krystal Biotech worth $11,648,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Krystal Biotech in the first quarter valued at $1,244,000. Intech Investment Management LLC boosted its holdings in Krystal Biotech by 11.4% in the first quarter. Intech Investment Management LLC now owns 12,078 shares of the company's stock valued at $2,178,000 after acquiring an additional 1,239 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after acquiring an additional 365,304 shares during the last quarter. Woodline Partners LP boosted its holdings in Krystal Biotech by 0.4% in the first quarter. Woodline Partners LP now owns 222,043 shares of the company's stock valued at $40,034,000 after acquiring an additional 941 shares during the last quarter. Finally, S Squared Technology LLC boosted its holdings in Krystal Biotech by 2.1% in the first quarter. S Squared Technology LLC now owns 97,215 shares of the company's stock valued at $17,528,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Up 2.1%

KRYS stock traded up $3.31 during midday trading on Friday, reaching $163.92. The company had a trading volume of 396,302 shares, compared to its average volume of 330,693. The stock has a 50 day moving average price of $147.67 and a 200 day moving average price of $152.22. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The firm has a market capitalization of $4.74 billion, a PE ratio of 33.36 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The company had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Chardan Capital reduced their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Bank of America reduced their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Citigroup restated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright restated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Monday. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $209.00.

Insider Activity

In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 49,800 shares of company stock worth $7,487,943 in the last three months. Insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).